| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6005001 (Pediatric) | KARO HLTHCARE | Pharmaceutical composition |
Nov, 2012
(11 years ago) | |
|
US5856355 (Pediatric) | KARO HLTHCARE | Pharmaceutical composition |
Nov, 2012
(11 years ago) | |
| US5681849 | KARO HLTHCARE | Pharmaceutical composition for topical applications |
Oct, 2014
(9 years ago) | |
|
US5681849 (Pediatric) | KARO HLTHCARE | Pharmaceutical composition for topical applications |
Apr, 2015
(9 years ago) | |
Lamisil is owned by Karo Hlthcare.
Lamisil contains Terbinafine.
Lamisil has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Lamisil are:
- US6005001*PED
- US5856355*PED
- US5681849
- US5681849*PED
Lamisil was authorised for market use on 29 April, 1998.
Lamisil is available in gel;topical dosage forms.
The generics of Lamisil are possible to be released after 28 April, 2015.
Drugs and Companies using TERBINAFINE ingredient
Market Authorisation Date: 29 April, 1998
Treatment: NA
Dosage: GEL;TOPICAL
More Information on Dosage
LAMISIL family patents
